At the physiological phenotype level, CRISPRa has also been used to increase the transcription of obesity risk genes SIM1 and MC4R, and to successfully rescue haploinsufficient obesity in mouse models—with the effects persisting up to 9 months post-treatment [80]. The gene discussed is MC4R; the disease is obesity due to melanocortin 4 receptor deficiency.